Loading...
OTCMTBRIF
Market cap13mUSD
Jan 10, Last price  
0.03USD
1D
16.00%
1Q
-11.30%
Name

Therma Bright Inc

Chart & Performance

D1W1MN
OTCM:TBRIF chart
P/E
P/S
724.55
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
14.11%
Rev. gr., 5y
30.44%
Revenues
26k
+9.08%
38,53543,810770,029250,858251,019172,75200001,7094,79331,16314,0966,9053,7833,883139,42723,89926,070
Net income
-2m
L-34.94%
-2,318,838-1,149,512-1,835,083-1,608,172-2,103,331-1,513,874-617,308-735,429860,04468,208-356,371-206,021-965,589-1,236,154-421,931-626,682-8,610,322-5,881,072-3,767,772-2,451,307
CFO
-1m
L-53.59%
-1,379,037-511,692-1,314,005-539,115-365,580-62,678-15,996-435-84,101-55,164-21,42554-178,487-359,890-189,723-104,944-2,855,507-3,800,002-2,174,861-1,009,279

Profile

Therma Bright Inc. engages in the development and sale of rapid COVID testing products, medical devices for pain management, devices to improve circulation, and devices for the cosmeceutical industry. The company's products include AcuVid, an antigen and antibody rapid screening test for COVID-19; InterceptCS, a cold sore prevention system, which provides controlled topical heat without the risk of burning the skin; Benepod, a hot and cold contrast therapy device for pain relief without pain relieving medication; Venowave, a medical compression pump designed to treat and alleviate the symptoms associated with poor circulation; and TherOZap, a thermal therapy insect device that reduces the inflammatory response, as well as relieves the symptoms of pain, itching, and inflammation associated with insect bites and stings. It serves consumers and medical professionals. The company was formerly known as The Jenex Corporation and changed its name to Therma Bright Inc. in February 2018. Therma Bright Inc. was incorporated in 2001 and is based in Toronto, Canada.
IPO date
Jul 11, 2001
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑072023‑072022‑072021‑072020‑072019‑072018‑072017‑072016‑072015‑07
Income
Revenues
26
9.08%
24
-82.86%
139
3,490.70%
Cost of revenue
1,161
3,627
5,824
Unusual Expense (Income)
NOPBT
(1,135)
(3,603)
(5,685)
NOPBT Margin
Operating Taxes
1
Tax Rate
NOPAT
(1,135)
(3,603)
(5,686)
Net income
(2,451)
-34.94%
(3,768)
-35.93%
(5,881)
-31.70%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,000
5,311
BB yield
Debt
Debt current
65
65
20
Long-term debt
25
76
161
Deferred revenue
Other long-term liabilities
Net debt
(2,029)
(881)
(3,106)
Cash flow
Cash from operating activities
(1,009)
(2,175)
(3,800)
CAPEX
(268)
Cash from investing activities
(138)
(691)
(205)
Cash from financing activities
966
(34)
5,306
FCF
(1,288)
(1,980)
(5,710)
Balance
Cash
1
182
3,082
Long term investments
2,119
840
205
Excess cash
2,119
1,021
3,280
Stockholders' equity
(12,962)
(13,943)
2,747
Invested Capital
14,352
14,078
111
ROIC
ROCE
EV
Common stock shares outstanding
315,916
242,840
228,454
Price
Market cap
EV
EBITDA
(1,036)
(3,528)
(5,533)
EV/EBITDA
Interest
9
13
1
Interest/NOPBT